{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"112","value":"8.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"}],"units":"Participants"}],"description":"Time to response was defined as the time from treatment enrollment to the first documentation of response (sCR, CR, VGPR or PR) based on IMWG criteria.","dispersionType":"Full Range","groups":[{"description":"Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle until the documentation of confirmed progressive disease (PD), intolerable toxicity, death, withdrawal of participation in the study/consent, lost to follow-up, or as long as they benefited from therapy according to the opinion of the responsible study investigator.","id":"OG000","title":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)"}],"paramType":"MEDIAN","populationDescription":"Includes participants with a response (sCR, VGPR or PR).","reportingStatus":"POSTED","timeFrame":"Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"Weeks"}